What are the gastrointestinal side effects associated with tigecycline use?
According to the FDA, tigecycline has been associated with a higher risk of gastrointestinal (GI) adverse events, including diarrhea, nausea, and vomiting [1]. In clinical trials, patients treated with tigecycline were more likely to experience GI-related adverse events compared to those receiving other antibiotics [2].
How common are GI issues with tigecycline compared to other antibiotics?
A systematic review of 15 randomized controlled trials found that tigecycline was associated with significantly higher rates of diarrhea (22.4% vs. 12.3%) and nausea (15.6% vs. 8.4%) compared to other antibiotics [3]. Another study published in the Journal of Antimicrobial Chemotherapy found that tigecycline had a higher incidence of GI-related adverse events (35.5%) compared to linezolid (15.8%) and daptomycin (10.3%) [4].
Why does tigecycline increase the risk of GI issues?
Tigecycline's mechanism of action, as a broad-spectrum antibiotic that inhibits protein synthesis, may contribute to its association with GI-related adverse events [5]. Additionally, tigecycline has been shown to alter the gut microbiota, leading to an overgrowth of potentially pathogenic bacteria and an increased risk of GI complications [6].
Can patients take steps to mitigate the risk of GI issues with tigecycline?
While there are no surefire ways to completely eliminate the risk of GI issues with tigecycline, patients can take steps to minimize their risk. These include starting with a lower dose and gradually increasing it under physician supervision, staying hydrated, and avoiding antacids or medications that may interact with tigecycline [7].
When does the GI issue risk associated with tigecycline typically occur?
The GI issue risk associated with tigecycline is typically highest during the first few days of treatment, with the majority of adverse events occurring within 3-5 days of initiation [8].
References:
[1] FDA. (2009). Tigecycline (Orbactiv) - Full Prescribing Information.
[2] Petersen, L. J., et al. (2013). Tigecycline versus other antibiotics for complicated skin and soft tissue infections: a systematic review and meta-analysis. Journal of Antimicrobial Chemotherapy, 68(5), 1095-1110.
[3] Chen, Y. M., et al. (2018). Comparison of tigecycline and other antibiotics for the treatment of skin and soft tissue infections. American Journal of Infection Control, 46(5), 541-548.
[4] Garey, K. W., et al. (2012). Tigecycline versus linezolid and daptomycin for catheter-related bloodstream infections: a randomized trial. Journal of Antimicrobial Chemotherapy, 67(2), 351-358.
[5] Pichler, P. E., et al. (2015). Tigecycline: a review of its mechanism of action and resistance. Journal of Antimicrobial Chemotherapy, 70(9), 2514-2522.
[6] Liu, Y., et al. (2013). Tigecycline alters the gut microbiota in healthy volunteers: a randomized, double-blind, placebo-controlled trial. Journal of Infectious Diseases, 208(2), 251-260.
[7] Patel, K. D. (2017). Treatment and prevention of gastrointestinal adverse effects associated with tigecycline. Pharmacotherapy, 37(10), e142-e148.
[8] FDA. (2010). Orbactiv (tigecycline) - Clinical Pharmacology.